Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition

Br J Dermatol. 2019 Sep;181(3):604-606. doi: 10.1111/bjd.17779. Epub 2019 May 14.

Authors

M Napolitano¹, M Megna², G Fabbrocini², S P Nisticò³, N Balato², S Dastoli³, C Patruno³

Affiliations

¹ Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy.
² Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
³ Department of Health Sciences, University Magna Graecia, Catanzaro, Italy.

PMID: 30768788
DOI: 10.1111/bjd.17779

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / adverse effects
Dermatologic Agents / adverse effects*
Drug Eruptions / diagnosis*
Drug Eruptions / immunology
Eczema / chemically induced
Eczema / diagnosis*
Eczema / immunology
Female
Humans
Interleukin-17 / antagonists & inhibitors*
Interleukin-17 / immunology
Male
Middle Aged
Psoriasis / drug therapy*
Psoriasis / immunology
Retrospective Studies
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
IL17A protein, human
Interleukin-17
ixekizumab
secukinumab